This meeting is directed at stakeholders in the biopharma industry in Europe who need to understand how medicines are assessed and valued by the public organisations that pay for them. Major themes include understanding the concept of 'value' as seen by payers and patients as well as how stronger evidence can be developed and communicated to budget holders. The goal is to ensure that there is rapid access to innovative and effective medicines in a manner that addresses the requirements of budget holders.
